Timothy Mangrum, MD
Internal Medicine · Nashville, TNNPI 1124067533
Payments from drug & device makers
Across 608 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Amgen$1K
- AstraZeneca$1K
- Lilly USA, LLC$999
- AbbVie$987
- Pfizer$945
- plus $3K from 25 others
What the payments were for
- Food & beverage$10,515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 164 | $2,688 |
| Amgen | 70 | $1,161 |
| AstraZeneca | 59 | $1,091 |
| Lilly USA, LLC | 56 | $999 |
| AbbVie(2 entities) | 61 | $987 |
| Pfizer | 56 | $945 |
| Merck | 16 | $287 |
| Sanofi-aventis U.S. LLC | 13 | $274 |
| Abbott | 12 | $234 |
| Exact Sciences | 13 | $229 |
| Boehringer Ingelheim | 13 | $219 |
| GSK | 12 | $197 |
| Bayer | 7 | $142 |
| Johnson & Johnson | 7 | $121 |
| Gilead | 7 | $117 |
| Novartis | 6 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $106 |
| Sensible Medical Innovations Inc | 1 | $97 |
| Kowa Pharmaceuticals America, Inc. | 5 | $76 |
| Sanofi Pasteur Inc. | 4 | $67 |
| Esperion Therapeutics, Inc. | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Lundbeck LLC | 1 | $27 |
| Orphalan Inc | 1 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 2 | $16 |
How this compares
$10,515 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 105 | $123,161 |
| EliquisApixaban | 141 | $119,009 |
| OzempicSemaglutide | 64 | $63,791 |
| XareltoRivaroxaban | 31 | $31,255 |
| Repatha SureclickEvolocumab | 22 | $21,255 |
| JardianceEmpagliflozin | 24 | $20,109 |
| LinzessLinaclotide | 18 | $14,943 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $14,161 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,598 |
| EntrestoSacubitril/Valsartan | 11 | $12,400 |
| Repatha SyringeEvolocumab | 11 | $10,897 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 75 | $5,861 |
| Atorvastatin Calcium | 424 | $5,848 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $5,054 |
| Allopurinol | 209 | $4,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $999 | $123,161105 claims |
| PfizerEliquis | $945 | $119,009141 claims |
| Novo NordiskOzempic | $2,688 | $63,79164 claims |
| Johnson & JohnsonXarelto | $121 | $31,25531 claims |
| Boehringer IngelheimJardiance | $219 | $20,10924 claims |
| AbbVieLinzess, Synthroid | $987 | $18,16376 claims |
| GSKBreo Ellipta | $197 | $14,16131 claims |
| NovartisEntresto | $116 | $12,40011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Nashville
- John AndersonNashville$1.5M
- Nancy DavisNashville$985K
- Wayne RileyNashville$536K
- Paul FerrellNashville$413K
- Cyndya Shibao MiyasatoNashville$364K
- Hilary TindleNashville$337K
- Harvey BowlesNashville$203K
- Jay MontgomeryNashville$174K
- Temidayo AbeNashville$113K
- Nader BahriNashville$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.